GLP-1 drugs on every 2026 Guam Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 1 stand-alone Part D plans in Guam cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | AARP Medicare Rx Preferred from UHC$0.00/moS5820-035 |
|---|---|
| Ozempicsemaglutide injection | Tier 3PA25%QL 3/28d |
| Mounjarotirzepatide injection | Tier 3PA25%QL 2/28d |
| Trulicitydulaglutide injection | Tier 3PA25%QL 2/28d |
| Ozempic tabletsoral semaglutide, formerly Rybelsus | Tier 3PA25%QL 30/30d |
| Wegovysemaglutide, weight | Not covered |
| Zepboundtirzepatide, weight | Not covered |
| Victozaliraglutide | Not covered |
| liraglutidegeneric Victoza | Not covered |
| Saxendaliraglutide, weight | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). |
| Byettaexenatide | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). |
| Bydureon BCiseexenatide extended-release | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). |
| orforglipronoral GLP-1, approved 2026 | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.